Dr Hernandez-Ilizaliturri on the Potential Advantages of Iopofosine I 131 in Waldenström Macroglobulinemia


Francisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.

Francisco Hernandez-Ilizaliturri, MD, director, Lymphoma Research, professor, oncology, Department of Medicine, head, Lymphoma Translational Research Lab, associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 (formerly CLR 131) compared with other available agents for patients with Waldenström macroglobulinemia.

Iopofosine I 131 was initially evaluated in the phase 2 CLOVER-1 trial (NCT02952508) across various B-cell malignancies. In this trial, the agent displayed notable efficacy and safety signals for heavily pretreated patients with Waldenström macroglobulinemia. These findings prompted the initiation of the CLOVER-WaM expansion cohort within the study for patients with Waldenström macroglobulinemia.

Initial data from the expansion cohort demonstrated durable responses and a tolerable safety profile for iopofosine I 131 in this population, according to Hernandez-Ilizaliturri. Despite the limited duration of follow-up, ongoing observations indicate that responses may continue to improve over time, even months after treatment completion, potentially providing iopofosine I 131 with a notable advantage over current therapies, Hernandez-Ilizaliturri states.

Distinguishing features of iopofosine I 131 include its novel mechanism of action and finite treatment duration, contrasting with continuous therapies, such as BTK inhibitors, Hernandez-Ilizaliturri explains. Despite producing deep responses, iopofosine I 131 offers the potential for treatment completion, which may be preferable for certain patients, he adds.

Safety data from 44 patients with Waldenström macroglobulinemia receiving iopofosine I 131 revealed that hematologic toxicities associated with the agent were primarily grade 1/2, with some instances of grade 3 or higher anemia or neutropenia, Hernandez-Ilizaliturri continues. Importantly, these adverse effects (AEs) were reversible, he adds. Unlike other available agents for patients with Waldenström macroglobulinemia, no vascular or renal AEs were reported with iopofosine I 131, he notes. These preliminary efficacy and safety findings underscore the favorable profile of this novel therapeutic option for patients with Waldenström macroglobulinemia, Hernandez-Ilizaliturri concludes.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD